Marlton-based Virtua Health is providing a leading-edge treatment for coronavirus, known as monoclonal antibodies. The medication, called bamlanivimab, helps non-hospitalized, high-risk patients with mild to moderate COVID-19.
In recent days, both The Washington Post and The New York Times have reported that many “overburdened hospitals” are not offering the treatment due to logistical challenges, but Virtua has provided this vital service to nearly 100 individuals since early December 2020.
“We’re very proud to be among the first in our region to offer this exciting new therapy,” said Dr. John Matsinger, executive vice president and chief operating officer for Virtua Health, South Jersey’s largest health system.
“Early studies suggest that bamlanivimab may resolve symptoms more quickly and possibly reduce progression of disease and associated hospitalizations. Further studies are ongoing regarding its use and effectiveness, but we are glad to have this treatment option as part of our larger toolkit for caring for those with COVID-19.”
Key facts about the treatment:
To find a Virtua doctor or location, please visit Virtua.org or call 1-888-VIRTUA-3.
To access more business news, visit NJB News Now.Related Articles: